French Brenus AS closes US$25m financing
French Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
Entries by Thomas Gabrielczyk
Von der Leyen names new EU Commissioners
European Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029.
ImmunOs Therapeutics AG raises US$11m in Series C financing
Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
Richter-Helm Biologics triples production capacity
After three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, vaccines, nanobodies and recombinant proteins.
Phoremost reports Series B extension
British protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Epsilogen Ltd completes £12.5m Series B expansion
A new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Swiss RNA maker Haya in huge licence deal
Swiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Roche with good interim clinical results
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Individor set to waive AEF0117 licence after Phase IIb failure
Following the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Nxera Pharma Ltd collects clinical US$35m milestone
Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.